DexCom Insider Sells $465,042 in Stock (DXCM)
DexCom (NASDAQ:DXCM) Insider Jorge A. Valdes sold 10,671 shares of DexCom stock on the open market in a transaction dated Thursday, August 21st. The stock was sold at an average price of $43.58, for a total transaction of $465,042.18. Following the transaction, the insider now directly owns 142,621 shares in the company, valued at approximately $6,215,423. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, August 8th. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $41.00.
Shares of DexCom (NASDAQ:DXCM) traded down 0.39% during mid-day trading on Monday, hitting $43.91. The stock had a trading volume of 364,197 shares. DexCom has a 52-week low of $25.49 and a 52-week high of $49.83. The stock has a 50-day moving average of $39.89 and a 200-day moving average of $38.97. The company’s market cap is $3.314 billion.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter in the prior year, the company posted ($0.14) earnings per share. The company’s quarterly revenue was up 64.2% on a year-over-year basis. Analysts expect that DexCom will post $-0.32 EPS for the current fiscal year.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.